Evidence Level:Sensitive: D – Preclinical
Title:
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
Excerpt:We assessed the cytotoxicity and internalization of ITC-6102RO in B7-H3 overexpressing cell lines in vitro and evaluated its anticancer efficacy and mode of action in B7-H3 overexpressing cell-derived and patient-derived xenograft models in vivo….ITC-6102RO inhibited cell viability in B7-H3-positive lung and breast cancer cell lines...
DOI:https://doi.org/10.1186/s12935-023-02991-x